Press Releases
Media Library
Social Media
Analyst Coverage
Annual and Interim Reports
Annual General Meeting
Annual Report 2016
Conflict Minerals Disclosure
Debt Investors
Dividend
Email Alerts
Events
Financial Highlights
Investor News
Our Strategy
Quarterly Results and Presentations
Recent Acquisitions
Shareholder Information
Stock Information
WHO WE ARE
Our Story
Rare Champions
Responsibility
Leadership
How We Operate
PATIENTS
Patient Services
Patient Advocacy
Therapeutic Areas
Humanitarian Access
Scholarships
R&D
Our R&D Strategy
RESEARCH AND EDUCATIONAL GRANTS
Science & Innovation
Clinical Trials
Pipeline
Collaborations
PRODUCTS
Product List
Manufacturing
Postmarketing Commitments
CAREERS
Search & Apply
Diversity & Inclusion
Culture & Values
Growing Your Career
Benefits
US Internship Program
Work Life Balance
Employee Profiles
Shire and Shionogi Announce Positive Topline Results for INTUNIV® (guanfacine hydrochloride prolonged release) Evaluated in Phase 3 Clinical Trial in Adults with ADHD
Shire Debuts MYDAYIS® and New Research at the 30th Annual Psych Congress
Shire Receives FDA Fast Track Designation for SHP607 for the Prevention of Chronic Lung Disease in Extremely Premature Infants
Elections for the interim dividend in respect of the six months to June 30, 2017
Shire’s Investigational Subcutaneous C1 esterase inhibitor (C1 INH [Human]) Liquid for Injection (SHP616) Significantly Reduces Hereditary Angioedema Monthly Attack Rate Versus Placebo in a Phase 3 Pivotal Trial
Shire to participate at two upcoming investor conferences
Total Voting Rights
Hurricane Harvey: Patient Support
Director/PDMR Shareholding
MYDAYIS™ (mixed salts of a single-entity amphetamine product), Shire’s New Once-Daily ADHD Treatment, Now Available in the U.S.
Shire Announces Collaboration with MicroHealth to Address Unique Needs of Hemophilia A and B Patients with Inhibitors
Shire plc Director and Senior Management Changes
Shire announces submission of lifitegrast Marketing Authorization Application for treatment of dry eye disease in Europe
Half-yearly Report
Shire reports strong Q2 2017 operating results and cash flow; updates full year guidance
Gap In Perceived and Actual Rates Of Prescription Stimulant Misuse, Abuse and Diversion Found Among College Students
Shire to announce second quarter 2017 results
Shire Expands Broad Monoclonal Antibody Research Platform, Enters License Agreement for Novimmune Bi-specific Antibody
Shire Obtains Injunction Against Roche to Address Incomplete and Misleading Statements Regarding Investigational Agent Emicizumab That May Impact Patient Safety
Additional Listing
LOAD MORE
Learn more
We make decisions that put patients first.
By following this link you will be leaving a Shire controlled website for a third party website. Please note that Shire is not responsible or liable for any third party website and the website may not be appropriate for all audiences.